B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
RAPP
Rapport TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
RAP-219 has already produced statistically significant Phase 2a proof-of-concept efficacy and tolerability data, management says FDA feedback supported advancement into two parallel Phase 3 trials, and the balance sheet plus Tenacia partnership provide time and some non-dilutive validation to pursue the program [#10-K-2026-03-10].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.3.
What can break
Cash burn accelerates as late-stage studies ramp, reviving dilution risk despite stated runway into 2H29.
Momentum
82
Value
41
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $52.00 · Bear $24.00Analysis 2026-04-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $62.25
Why
Momentum82 · Δ7d -4.8
Value41 · Δ7d -0.0
Sentiment41 · Δ7d +9.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +9.3.
Contradictions & invalidation
- • Cash burn accelerates as late-stage studies ramp, reviving dilution risk despite stated runway into 2H29.
- • Phase 2a tolerability and efficacy do not translate cleanly into larger registrational trials.
- • This remains a single-asset-heavy, pre-commercial biotech story with limited near-term external news flow; the stock still depends on Phase 3 start and execution, and any delay, safety surprise, or faster-than-expected burn could compress valuation despite the current cash position [#10-K-2026-03-10].
Catalyst clock
2026-05-15
Q1 2026 filing to confirm burn and runway after Phase 3 prep
Lead driver: Sentiment · See AI snapshot
Momentum
82
9% active weight
Current posture
7d trendSoftening
Δ7d
-4.8
Δ21d
-8.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
41
62% active weight
Current posture
7d trendImproving
Δ7d
+9.3
Δ21d
+4.5
Why this grade
Composite grade D. Momentum 81.7 / Value 41.2 / Sentiment 41.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-17. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.32B
Beta
-
Shares Out
47.98M
P/E (TTM) · Derived
-16.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-22.56
Rev YoY
-
EPS YoY
+58.1%
Gross Margin
+95.2%
Op Margin
-
Net Debt
-$479.16M
Current Ratio
15.72
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data